Singleton Hospital holds meeting to explain surface image guided radiation therapy

Having recently installed an Elekta Versa HD linear accelerator, Singleton Hospital in Swansea is planning on using the C-RAD surface image guided radiation therapy (SIGRT system), supplied by Vertec Scientific, for patients receiving breast radiotherapy treatment when the machine goes live in spring. SIGRT is a technique that helps to deliver highly accurate radiotherapy treatments.

In preparation, the RT physics team at the hospital held an open meeting to explain their choices and the technologies involved, and this attracted more than 30 delegates. Chaired by Singleton Hospital RT physicist Adam Selby, the meeting began with a welcome from Swansea’s head of radiotherapy physics Dr Ryan Lewis and C-RAD’s president EIMEA Dirk Feynhagen. They were followed by presentations from C-RAD applications specialist Beatrice Akinrimisi who touched on the system options, clinical application and workflow, and the impact of the system in other RT centres. Selby then detailed the team’s experience with C-RAD, why they chose it in the first place and future plans for clinical implementation.

Akinrimisi returned for a further session called ‘Under the bonnet’ where she outlined the physics behind how the system works, commissioning and QC requirements. The afternoon saw a hands-on demonstration of the C-RAD Catalyst HD system on the hospital’s Versa HD linac and, in a parallel session, presentations by Vertec product specialist David White and radiotherapy physics technologist Joe Flaherty on automated breast planning using the Philips Pinnacle treatment planning system.

Picture: Delegates pictured with (front row, from third left) Vertec product specialist David White, RT physicist Adam Selby, C-RAD applications specialist Beatrice Akinrimisi and C-RAD president EIMEA Dirk Feynhagen.

Published on page 2 of the February 2020 issue of RAD Magazine.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more